Published: Apr 13, 2021
Jiuquan, China, April 13, 2021 (GLOBE NEWSWIRE)
Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections. In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.
National Reimbursement Drug List is the list of products eligible for reimbursement in China, as maintained by the National Healthcare Commission of China. The National Essential Medicines List is one of the core contents of the essential medicines system. The system requires that all government-run primary health care institutions be equi
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The new facility. Pic:BeiGene BeiGene has announced approval from the China National Medical Products Administration (NMPA) to begin manufacturing its anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China.
Production will start immediately at the site, which covers more than one million square feet (100,000 square meters) and boasts 8,000 liters of biologics capacity.
An additional phase of construction is set to bring total capacity up to 64,000 liters by the end of 2022.
BeiGene says the site represents the first paperless biological manufacturing facility in China: and integrates new technologies such as 3D modeling, digital twin, augmented interfaces, and AI to improve quality and efficiency.
Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) $BGNE#BTKi BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China. At over one million square feet (100,000 square meters) and 8,000 liters of biologics capacity approved for commercial supply, this wholly owned facility will immediately begin production of commercial supply of tislelizumab for the China market. An additional phase of construction currently in progress to bring total capacity to 64,000 liters is expected to be completed by the end of 2022.
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.